535 W 24TH STREET, NEW YORK, NY
Reports First Quarter 2026 Financial Results and Highlights Recent Updates
Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
Investor Presentation
Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
Q1
FY 2025
Q3
Q2
FY 2024
Notice of Late Filing for Quarterly Report
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement